The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. BioCryst Pharmaceuticals's Revenue for the
three
months ended in Mar. 2026 was $156.4 Mil. BioCryst Pharmaceuticals's average Accounts Receivable for the
three
months ended in Mar. 2026 was $108.0 Mil.
Hence, BioCryst Pharmaceuticals's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.45.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
BioCryst Pharmaceuticals Receivables Turnover Related Terms
BioCryst Pharmaceuticals Receivables Turnover Historical Data
* Premium members only.
The historical data trend for BioCryst Pharmaceuticals's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCRX vs SUPN, PBH, AMLX: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCryst Pharmaceuticals Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where BioCryst Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCryst Pharmaceuticals (BCRX) has a Receivables Turnover of 1.45 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BioCryst Pharmaceuticals and its competitors. According to the industry distribution chart, BioCryst Pharmaceuticals ranks #163 out of 950 companies in the Drug Manufacturers industry, placing it in the top 17.2%.
Is BioCryst Pharmaceuticals' Receivables Turnover too high?
BioCryst Pharmaceuticals' current Receivables Turnover is 1.45. The Drug Manufacturers industry median Receivables Turnover is 5.07. BioCryst Pharmaceuticals' value of 1.45 is 71.4% below this industry median. Based on the distribution chart, BioCryst Pharmaceuticals ranks #163 out of 950 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioCryst Pharmaceuticals has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' Receivables Turnover compare to SUPN and PBH?
According to the Drug Manufacturers industry distribution chart, BioCryst Pharmaceuticals ranks #163 out of 950 companies for Receivables Turnover. This places BioCryst Pharmaceuticals in the top 17% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.07. BioCryst Pharmaceuticals' value of 1.45 is 71.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioCryst Pharmaceuticals's current Receivables Turnover of 1.45 is 71.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BioCryst Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioCryst Pharmaceuticals's current Receivables Turnover is 1.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.51, compared to a current price of $10.45 — trading 16.5% below its estimated fair value. The current Receivables Turnover is 1.45 and 71.4% below the Drug Manufacturers industry median of 5.07. BioCryst Pharmaceuticals' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For BioCryst Pharmaceuticals (BCRX), the current Receivables Turnover is 1.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioCryst Pharmaceuticals (BCRX) Overvalued in 2026?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued.
The current stock price of $10.45 is trading 16.5% below its estimated GF Value™ of $12.51.
GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for BCRX:
Receivables Turnover: 1.45
GF Value™: $12.51 vs. price of $10.45 (16.5% below fair value)
Industry Position: 71.4% below the Drug Manufacturers median (#163 of 950)
No single metric tells the full story. See the BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
66GF Score
Get the complete analysis for BCRX
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCRX has been successfully added to your 
